These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 21877913

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X, Deng H, Zhang X, Yang D, Yan J, Yao B, Weng J, Xu W.
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes].
    Li YB, Zhu HL, Yao B, Huang ZM, Ou XZ, Xiao YB, Weng JP.
    Zhonghua Yi Xue Za Zhi; 2005 Mar 09; 85(9):602-5. PubMed ID: 15949356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 09; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 8. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y.
    Diabetes Technol Ther; 2013 Oct 09; 15(10):859-69. PubMed ID: 23991629
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
    Ke W, Liu L, Liu J, Chen A, Deng W, Zhang P, Cao X, Liao Z, Xiao H, Liu J, Li Y.
    J Diabetes Res; 2016 Oct 09; 2016():6839735. PubMed ID: 26640805
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ, Yao MY, Ma JX, Xue P, Li YK.
    Endocr J; 2019 Oct 28; 66(10):871-880. PubMed ID: 31243192
    [Abstract] [Full Text] [Related]

  • 15. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF, Fu LY, Zhang WL, Su XF, Wu JD, Sun J, Ye L, Ma JH.
    J Diabetes Res; 2016 Oct 28; 2016():1028945. PubMed ID: 26839889
    [Abstract] [Full Text] [Related]

  • 16. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
    Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H.
    Lancet; 2008 May 24; 371(9626):1753-60. PubMed ID: 18502299
    [Abstract] [Full Text] [Related]

  • 17. Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial.
    Yuan G, Hu H, Wang S, Yang Q, Yu S, Sun W, Qian W, Mao C, Zhou L, Chen D, Wang Z, Gong Q, Wang D.
    Endocr J; 2015 May 24; 62(9):817-34. PubMed ID: 26194272
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients.
    Liu J, Liu J, Fang D, Liu L, Huang Z, Wan X, Cao X, Li Y.
    Endocr J; 2013 May 24; 60(6):725-32. PubMed ID: 23428844
    [Abstract] [Full Text] [Related]

  • 20. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.
    Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J.
    Diabetes Care; 2004 Nov 24; 27(11):2597-602. PubMed ID: 15504992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.